Sanofi reports CARD study results presented at ESMO, published in NEJM
Data published in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer, mCRPC, previously treated with docetaxel and who progressed within 12 months on an androgen receptor-targeted agent experienced significantly longer radiographic progression free survival, or rPFS, with Jevtana plus prednisone compared with abiraterone plus prednisone or enzalutamide, Sanofi announced. Overall survival with Jevtana was also significantly longer, the company said. These findings from the CARD study were presented today in the Presidential Symposium of the 2019 European Society of Medical Oncology Congress, or ESMO. The study's primary endpoint was rPFS, which more than doubled with Jevtana treatment compared to abiraterone or enzalutamide. Patients treated with Jevtana experienced an improvement in rPFS in all pre-specified subgroups, irrespective of the timing of the previous alternative AR-targeted agent, before or after docetaxel. Jevtana also significantly improved a key secondary endpoint, OS, reducing the risk of death from any cause by 36% compared with abiraterone or enzalutamide. Other key secondary endpoints all favored Jevtana, the company said.